[SCHEDULE 13G/A] Amicus Therapeutics, Inc SEC Filing

Rhea-AI Filing Summary

Perceptive Advisors and related parties report a 2.4% shared ownership stake in Amicus Therapeutics (FOLD). The filing shows Perceptive Life Sciences Master Fund, Ltd. directly holds 7,412,830 shares and Perceptive Advisors LLC, as manager, and Joseph Edelman, as managing member, report shared voting and dispositive power over those shares. No sole voting or dispositive power is claimed. The ownership percentage is calculated using 308,239,374 shares outstanding. The filing states the position is not held to influence control of the company.

Positive

• Clear regulatory disclosure of a 2.4% beneficial interest in Amicus Therapeutics with specific share count and attribution
• All reporting persons identified and signed, including statement that holdings are not intended to influence control

Negative

• None.

Insights

Financial Analyst

TL;DR: A 2.4% stake is disclosed; it is modest and below thresholds that typically trigger activist or control concerns.

The Schedule 13G/A reports 7,412,830 shares representing 2.4% of Amicus Therapeutics based on 308,239,374 shares outstanding. The shares are held by the Master Fund with shared voting and dispositive power attributed to Perceptive Advisors and Joseph Edelman. Because the ownership is below 5%, this filing is consistent with passive or investment-adviser reporting rather than an intent to influence control. Material market impact is likely limited given the size relative to the float.

Corporate Governance Expert

TL;DR: Disclosure is procedurally complete; shared voting power is noted but the position remains non-controlling.

The filing clearly identifies the reporting persons, jurisdictional details, and allocation of voting and dispositive power, with signatures by Joseph Edelman. The certification affirms the position is not intended to change or influence control. From a governance standpoint, the report fulfills regulatory transparency requirements but does not indicate any group formation, control actions, or governance agenda.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

Amicus Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

03152W109

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 03152W109

1

Names of Reporting Persons

Perceptive Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,412,830.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,412,830.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,412,830.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.4 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 03152W109

1

Names of Reporting Persons

Joseph Edelman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,412,830.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,412,830.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,412,830.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.4 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 03152W109

1

Names of Reporting Persons

Perceptive Life Sciences Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,412,830.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,412,830.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,412,830.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.4 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Amicus Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 47 Hulfish Street, Princeton, NJ 08542
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.01 per share (the "Common Stock") of Amicus Therapeutics, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
(c)	Citizenship: Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
(d)	Title of class of securities: Common Stock, par value $0.01 per share
(e)	CUSIP No.: 03152W109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 308,239,374 shares of Common Stock outstanding as of July 25, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 31, 2025. The Master Fund directly holds 7,412,830 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.
(b)	Percent of class: Perceptive Advisors: 2.4% Mr. Edelman: 2.4% Master Fund: 2.4%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
	(ii) Shared power to vote or to direct the vote: Perceptive Advisors: 7,412,830 Mr. Edelman: 7,412,830 Master Fund: 7,412,830
	(iii) Sole power to dispose or to direct the disposition of: Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
	(iv) Shared power to dispose or to direct the disposition of: Perceptive Advisors: 7,412,830 Mr. Edelman: 7,412,830 Master Fund: 7,412,830
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Perceptive Advisors LLC

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman, Managing Member
Date:	08/14/2025

Joseph Edelman

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman
Date:	08/14/2025

Perceptive Life Sciences Master Fund, Ltd.

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman, Managing Member
Date:	08/14/2025

FAQ

How many Amicus Therapeutics (FOLD) shares does Perceptive report owning?

The filing reports the Master Fund directly holds 7,412,830 shares, representing 2.4% of Amicus' common stock.

Does Perceptive Advisors or Joseph Edelman claim sole voting or dispositive power over FOLD shares?

No. The filing shows 0 shares with sole voting or dispositive power and 7,412,830 shares with shared voting and dispositive power.

Is this filing filed as an intent to influence control of Amicus Therapeutics (FOLD)?

No. The certification states the securities were not acquired and are not held to change or influence control of the issuer.

What outstanding share count was used to calculate the 2.4% ownership in FOLD?

The percentage is based on 308,239,374 shares outstanding, as reported in the issuer's quarterly report.

When was the Schedule 13G/A signed?

The signatures in the filing are dated 08/14/2025.